MX2020003217A - Coagonistas de accion prolongada de los receptores de glucagon y glp-1. - Google Patents

Coagonistas de accion prolongada de los receptores de glucagon y glp-1.

Info

Publication number
MX2020003217A
MX2020003217A MX2020003217A MX2020003217A MX2020003217A MX 2020003217 A MX2020003217 A MX 2020003217A MX 2020003217 A MX2020003217 A MX 2020003217A MX 2020003217 A MX2020003217 A MX 2020003217A MX 2020003217 A MX2020003217 A MX 2020003217A
Authority
MX
Mexico
Prior art keywords
glp
glucagon
agonists
receptors
acting
Prior art date
Application number
MX2020003217A
Other languages
English (en)
Inventor
Yuping Zhu
Anandan Palani
Qiaolin Deng
Chunhui Huang
Federica Orvieto
Elisabetta Bianchi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020003217A publication Critical patent/MX2020003217A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen coagonistas de acción prolongada de los receptores de glucagón y GLP-1.
MX2020003217A 2017-09-25 2018-09-21 Coagonistas de accion prolongada de los receptores de glucagon y glp-1. MX2020003217A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762562674P 2017-09-25 2017-09-25
PCT/US2018/052124 WO2019060660A1 (en) 2017-09-25 2018-09-21 CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Publications (1)

Publication Number Publication Date
MX2020003217A true MX2020003217A (es) 2020-07-29

Family

ID=65810991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003217A MX2020003217A (es) 2017-09-25 2018-09-21 Coagonistas de accion prolongada de los receptores de glucagon y glp-1.

Country Status (11)

Country Link
US (1) US11566057B2 (es)
EP (1) EP3700550A4 (es)
JP (3) JP2020535138A (es)
KR (1) KR102505628B1 (es)
CN (1) CN111132690A (es)
AU (1) AU2018338184B2 (es)
BR (1) BR112020005841A8 (es)
CA (2) CA3220650A1 (es)
MA (1) MA50474A (es)
MX (1) MX2020003217A (es)
WO (1) WO2019060660A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114980913B (zh) * 2019-10-22 2025-09-30 努里塔斯有限公司 非酒精性脂肪性肝病的治疗
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CA3226846A1 (en) * 2021-07-30 2023-02-02 Boehringer Ingelheim International Gmbh Dose regimen for long-acting glp1/glucagon receptor agonists
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024252366A1 (en) * 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
GB0308801D0 (en) * 2003-04-16 2003-05-21 Celltech R&D Ltd Chemical compounds
CA2612063A1 (en) 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN103857408B (zh) 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
CA3093383A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
WO2017074798A2 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors
US20190175744A1 (en) 2016-03-18 2019-06-13 Merck Sharp & Dohme Corp. Insulin-incretin conjugates

Also Published As

Publication number Publication date
JP2020535138A (ja) 2020-12-03
US20200270325A1 (en) 2020-08-27
JP2023071869A (ja) 2023-05-23
EP3700550A1 (en) 2020-09-02
EP3700550A4 (en) 2022-02-23
RU2020114220A (ru) 2021-10-27
BR112020005841A2 (pt) 2020-11-17
CA3076496A1 (en) 2019-03-28
AU2018338184A1 (en) 2020-03-12
JP2023171744A (ja) 2023-12-05
WO2019060660A1 (en) 2019-03-28
KR20200057059A (ko) 2020-05-25
RU2020114220A3 (es) 2021-12-28
CA3220650A1 (en) 2019-03-28
CN111132690A (zh) 2020-05-08
US11566057B2 (en) 2023-01-31
MA50474A (fr) 2020-09-02
BR112020005841A8 (pt) 2023-04-11
AU2018338184B2 (en) 2023-04-13
KR102505628B1 (ko) 2023-03-02

Similar Documents

Publication Publication Date Title
TN2018000228A1 (en) Triple activator activating glucagon, glp-1 and gip receptor
IL279300A (en) 1-GLP agonist receptors and their use
IL279224A (en) 1-GLP agonist receptors and their use
IL251741A0 (en) Co-agonists for glucagon and 1- glp receptors
IL267288B (en) glp-1 receptor agonists and their use
PL3704143T3 (pl) Chemo-enzymatyczna synteza liraglutydu, semaglutydu i glp-1
WO2017074798A3 (en) Long-acting co-agonists of the glucagon and glp-1 receptors
WO2017100107A3 (en) Co-agonists of the glucagon and glp-1 receptors
CA3013532A1 (en) Liraglutide in cardiovascular conditions
MY199261A (en) Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
HK1235411A1 (en) Co-agonists of the glucagon and glp-1 receptors
PH32017001133S1 (en) Chair